Sigilon debuts with $23.5M series A

Sigilon Therapeutics Inc. (Cambridge, Mass.) emerged from Flagship Pioneering's VentureLabs incubator with $23.5 million in series A funding from the VC.

The newco will use its biocompatible Afibromer technology to develop encapsulated cell therapies for hematologic, enzyme deficiency, endocrine and metabolic disorders...